New insider activity at Serina Therapeutics ( (SER) ) has taken place on October 29, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CSO Moreadith Randall recently sold 5,551 shares of Serina Therapeutics stock, amounting to a total transaction value of $27,532.
Recent Updates on SER stock
In recent developments for Serina Therapeutics, the company announced the receipt of the first $5 million from a $20 million financing agreement to support the registrational trial of SER-252 for advanced Parkinson’s disease, with the trial set to begin in Q4 2025. Despite this progress, the stock’s overall outlook remains neutral due to poor financial performance, characterized by significant losses, high liabilities, and negative cash flow. The technical analysis indicates no strong trend, and the valuation is unattractive with a negative P/E ratio and lack of dividend yield, suggesting a high-risk investment. These factors have led to a Hold rating with a $5.00 price target.
Spark’s Take on SER Stock
According to Spark, TipRanks’ AI Analyst, SER is a Underperform.
Serina Therapeutics’ overall stock score is primarily impacted by its poor financial performance, which is the most significant factor. The technical analysis also suggests a bearish trend, further weighing down the score. The valuation is unfavorable due to the negative P/E ratio and lack of dividend yield, indicating limited investor appeal. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on SER stock, click here.
More about Serina Therapeutics
YTD Price Performance: -0.20%
Average Trading Volume: 126,513
Technical Sentiment Signal: Sell
Current Market Cap: $52.18M